NCT03927001进行中（未招募）不适用
Prospective, Open-Label, Multi-Center Single-Arm Trial Designed to Assess the Safety, Performance and Efficacy of the NeVa Stent Retriever in the Treatment of Large Vessel Occlusion Strokes
Vesalio1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2019年4月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Recanalization rate of the occluded target vessel
研究概览
简要总结
A prospective, open label, single-arm 90-day study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.
详细描述
This is a prospective, open label, multi-center, single-arm trial designed to assess the safety, performance and efficacy of the NeVa stent retriever in the treatment of large vessel occlusion strokes. Up to 150 subjects at up 20 sites will participate in the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke, and subject belongs to one of the following subgroups:
- •Subject has failed IV t-PA therapy
- •Subject is contraindicated for IV t-PA administration
- •IV-tPA given within 3 hours of symptom onset
- •Age ≥18 and less than equal to 85
- •NIHSS score ≥ 8 and ≤ 25
- •Prestroke mRS score of ≤ 1
- •Intracranial arterial occlusion of the distal intracranial carotid artery or middle cerebral artery (M1/M2), anterior cerebral artery (ACA), posterior cerebral artery (PCA), basilar artery, or vertebral artery demonstrated with DSA.
- •Thrombectomy procedure can be initiated within 8 hours from symptom onset (defined as time last known well [TLKW]) and at least one NeVa pass occurring within 8 hours
- •Imaging Inclusion Criteria:
- •Non-Contrast CT Selection (if CT Perfusion or MRI not utilized): ASPECTS 6-10 , or
- •CT Perfusion core ≤50 cc, or
- •MRI DWI core ≤50 cc
- •Subject or (legal) representative or independent physician (if approved by site's regional ethics committee, see site's informed consent form) is able and willing to give informed consent prior to the interventions.
排除标准
- •Pre-existing medical neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor (e.g. Aricept).
- •Cardiopulmonary resuscitation, significant cardiac arrhythmia, evidence of ongoing myocardial infarction, concern for pre-treatment pulmonary aspiration.
- •Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.
- •Cerebral vasculitis
- •History of severe allergy to contrast medium.
- •Known allergy to NeVa materials (nitinol, stainless steel);
- •Suspicion of aortic dissection, septic embolus, or bacterial endocarditis
- •Systemic infection
- •Significant mass effect with midline shift
- •Evidence of intracranial tumor (except small meningioma [≤ 3cm])
- •Any CT or MRI evidence of acute hemorrhage products on presentation
- •Inability to deploy NeVA device for at least one pass for any other reason
- •Life expectancy less than 6 months
- •Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.
- •Active malignancy
- •Stenosis or occlusion in a proximal vessel requiring treatment or preventing access to the thrombus.
结局指标
主要结局
Recanalization rate of the occluded target vessel
时间窗: post-procedure day 0
Recanalization rate of the occluded target vessel (defined by an eTICI score ≥ 2b) following three or less passes using the NeVa device(s).
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
The Vesalio NeVa Stent Retriever Study for Treatment of Large Vessel Occlusion Strokes: CLEAR StudyAcute Ischemic StrokeNCT04514562Vesalio120
终止
不适用
Severe OSA Study (SOS)Obstructive Sleep ApneaSleep ApneaNCT05445869ProSomnus Sleep Technologies35
进行中（未招募）
2 期
A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe ADAtopic DermatitisNCT05905133Suzhou Connect Biopharmaceuticals, Ltd.360
招募中
不适用
A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSLPrimary Central Nervous System LymphomaNCT06445257Huai'an First People's Hospital30
进行中（未招募）
不适用
PROACTIVE-HF IDE Trial Heart Failure NYHA Class IIIHeart Failure NYHA Class IIINCT04089059Endotronix, Inc.738